US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CAR-T Concept

1,433.26

+13.930.98%

Number of Gainers:2

Number of Losers:1

Number of Flat:- -

PE:- -

High:1,434.37

Open:1,417.73

Low:1,415.68

Close:1,419.51

Loading ...

U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund

Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79

Simply Wall St.

Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus

Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus

Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)

Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)

Salesforce Stock Falls On Weak Revenue Outlook Amid Artificial Intelligence Push

Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program

Novartis Stockholder Sandoz to Reportedly Sell 26.5 Million Shares

MT Newswires Live

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors

Market Chatter: Emasan Offering to Sell 1.2% Stake in Novartis

MT Newswires Live

Novartis holder Emasan selling 26.5M shares, Bloomberg reports

Emasan files to sell 26.5M shares of Novartis, Bloomberg reports

4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/BK4578/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4578"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","market":"US","secType":"PLATE","nameCN":"CAR-T Concept","latestPrice":1433.4493,"timestamp":1741615295030,"preClose":1419.5145,"halted":0,"volume":981747,"delay":0,"changeRate":0.009817,"change":13.934814,"pbRate":5.836914,"amount":114387445.442705,"amplitude":0.013169,"prevYearClose":1164.883,"fiveDayClose":1375.8962,"twentyDayClose":1248.9824,"turnoverRate":0.000313,"marketCap":378148698820,"floatMarketCap":367112956016,"peRate":30.498118},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4578\",,,,,undefined,":{"symbol":"BK4578","high":1434.372,"amplitude":0.013169,"preClose":1419.5145,"low":1415.6777,"pbRate":"5.836914","latestPrice":1433.2605,"volume":984525,"delay":0,"open":1417.7288,"prevYearClose":1164.883,"prevWeekClose":1419.5145,"prevMonthClose":1356.2184,"prevQuarterClose":1164.883,"fiveDayClose":1375.8962,"twentyDayClose":1248.9824,"sixtyDayClose":1184.3591,"secType":"PLATE","market":"US","turnoverRate":0.000313,"peRate":30.498118,"marketCap":378165099204,"floatMarketCap":367129159792,"timestamp":1741615299532,"nameCN":"CAR-T Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4578\",,,,undefined,":{"bkCode":"BK4578","up":2,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4578\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516150651","title":"U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund","url":"https://stock-news.laohu8.com/highlight/detail?id=2516150651","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516150651?lang=en_us&edition=fundamental","pubTime":"2025-03-03 15:43","pubTimestamp":1740987813,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP- Autodesk, Fedex, Morgan Stanley Direct Lending Fund March 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nL3N3PM0FA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CABO","MSDL","GILD","LU0054578231.USD","UHS","LU0724618433.USD","IE00BN0W2W23.USD","IE00B3T34201.USD","FSS","IE00B2PGVK34.USD","LU1978683503.SGD","HUBB","LU1992135399.USD","BK4131","GEV","LU2125910336.SGD","BK4568","PRAX","BJ","GTLS","LU2298064838.USD","PUBM","LU0251142724.SGD","BLD","LU0323240290.USD","LU0345774631.USD","LU2065731478.USD","BK4185","ARDT","DCBO","IE00B66KJ199.SGD","LU1721428933.USD","LU2326559502.SGD","FDX","LU2087621335.USD","LU2265009873.SGD","BK4096","LU1066051498.USD","IE00B19Z9Z06.USD","BK4578","ADSK","ASTH","IE00BZ9MQY76.HKD","FOXF","VTR","LU0289739699.SGD","LU0889565916.HKD","BK4088","WTS"],"gpt_icon":1},{"id":"2516556797","title":"Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.79","url":"https://stock-news.laohu8.com/highlight/detail?id=2516556797","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516556797?lang=en_us&edition=fundamental","pubTime":"2025-03-01 20:53","pubTimestamp":1740833610,"startTime":"0","endTime":"0","summary":"The board of Gilead Sciences, Inc.  has announced that it will be paying its dividend of $0.79 on the 28th of March, an increased payment from last year's comparable dividend. This takes the annual payment to 2.8% of the current stock price, which is about average for the industry.Gilead Sciences' Future Dividend Projections Appear Well Covered By Earnings. We aren't too impressed by dividend yields unless they can be sustained over time. Prior to this announcement, the company was paying out 800% of what it was earning, however the dividend was quite comfortably covered by free cash flows at a cash payout ratio of only 38%. Generally, we think cash is more important than accounting measures of profit, so with the cash flows easily covering the dividend, we don't think there is much reason to worry.Analysts expect a massive rise in earnings per share in the next year. Assuming the dividend continues along recent trends, we estimate that the payout ratio could reach 47%, which is in a c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gilead-sciences-nasdaq-gild-increasing-125330339.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU1839511570.USD","LU0058720904.USD","LU2210150020.SGD","PSQ","BK4578","BK4583","LU2468319806.SGD","BK4568","LU1066053197.SGD","LU0889565916.HKD","NVIW.SI","IE00B19Z3B42.SGD",".IXIC","LU2210149790.SGD","BK4112","IE00BSNM7G36.USD","MNQmain","IE00B3T34201.USD","LU2087621335.USD","IE00B64PRP62.GBP","IE0002270589.USD","QID","BK4588","LU2095319765.USD","IE00B7SZLL34.SGD","QLD","LU0234570918.USD","USJW.SI","IE00BZ1G4Q59.USD","BK4532","TSYW.SI","NDAQ","IE00BGHQF748.EUR","LU0320765992.SGD","LU1066051498.USD","SQQQ","IE00BKPKM429.USD","LU0289739699.SGD","LU0109394709.USD","TQQQ","LU1585245621.USD","IE00B3QW5Z07.USD","GILD","LU1571399168.USD","USAW.SI","BK4585","NQmain","BK4566"],"gpt_icon":1},{"id":"2516130552","title":"Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516130552","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516130552?lang=en_us&edition=fundamental","pubTime":"2025-03-01 02:12","pubTimestamp":1740766320,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. KYMR reported a fourth-quarter 2024 loss of 88 cents per share, wider than the Zacks Consensus Estimate of a loss of 76 cents. In the year-ago quarter, Kymera reported a loss of 25 cents per share.The year-over-year deterioration was due to lower collaboration revenues and higher operating expenses.Collaboration revenues totaled $7.4 million, which missed the Zacks Consensus Estimate of $13 million.In the year-ago quarter, Kymera earned collaboration revenues of $47.9 million due to the recognition of milestone payments related to the advancement of KT-474 into phase II testing under its collaboration with pharma bigwig Sanofi SNY.Shares of KYMR have lost 30.1% year to date compared with the industry’s decline of 8%.In October, Kymera initiated the phase I study on KT-621 in healthy volunteers. KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6.Kymera intends to advance KT-295, an investigational, first-in-class, once daily, oral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymeras-q4-loss-wider-expected-181200761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066051498.USD","GILD","BK4585","KYMR","IE00BKVL7J92.USD","LU2468319806.SGD","LU1839511570.USD","LU2087621335.USD","LU1066053197.SGD","BK4532","IE00BZ1G4Q59.USD","LU0058720904.USD","LU2089984988.USD","IE00B7SZLL34.SGD","BK4550","LU0234570918.USD","IE00BSNM7G36.USD","LU0109394709.USD","BK4007","IE00BFXG1179.USD","LU1571399168.USD","SNY","IE0002270589.USD","BK4568","BMRN","BK4583","LU0889565916.HKD","IE00B3T34201.USD","BK4578","LU0320765992.SGD","IE00B19Z3B42.SGD","BK4139","LU1585245621.USD","BK4566","BK4588","LU1430594728.SGD","LU0289739699.SGD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2516379060","title":"Xenon Q4 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379060","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379060?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:36","pubTimestamp":1740753360,"startTime":"0","endTime":"0","summary":"Find the latest EPS estimates and surprises on Zacks Earnings Calendar.In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX for XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well.NBI-921352 is a selective Nav1.6 sodium channel inhibitor. Neurocrine is currently evaluating NBI-921352 in a phase II study to treat patients aged 2-21 years with SCN8A developmental and epileptic encephalopathy. Per the terms of the agreement with NBIX, Xenon is eligible to receive certain clinical, regulatory and commercial milestone-based payments, as well as royalties on future sales.XENE, in collaboration with Neurocrine, is also currently evaluating NBI-921355, a Nav1.2/1.6 inhibitor, as a potential treatment for certain types of epilepsy. In the earnings releas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-q4-loss-narrower-expected-143600608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0320765992.SGD","IE00B19Z3B42.SGD","IE0002270589.USD","IE00BKVL7J92.USD","LU2089984988.USD","BK4578","NBIX","BK4583","LU1571399168.USD","LU2065171311.SGD","GILD","LU0109394709.USD","LU2324357040.USD","LU0823416689.USD","BK4588","IE00BSNM7G36.USD","LU1839511570.USD","LU2087621335.USD","LU2468319806.SGD","LU1585245621.USD","IE00BZ1G4Q59.USD","BMRN","ABVC","LU0234570918.USD","BK4566","BK4139","LU2065170008.USD","IE00B3T34201.USD","BK4568","IE00B19Z3581.USD","LU0289739699.SGD","LU1430594728.SGD","LU2065171402.SGD","IE00B7SZLL34.SGD","XENE","LU1066051498.USD","BK4532","LU2065169927.USD","LU0058720904.USD","LU0889565916.HKD","LU1066053197.SGD","BK4585","BK4550"],"gpt_icon":0},{"id":"2514327499","title":"Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514327499","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514327499?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:00","pubTimestamp":1740751200,"startTime":"0","endTime":"0","summary":"Two-year efficacy and safety data analyses from Phase III SUNSHINE and SUNRISE trials of continuous Cosentyx  treatment in HS to be presented. New analyses of 52-week data from Phase III REMIX pivotal trials of investigational remibrutinib, demonstrating impact in key clinical outcomes for patients with CSU also to be presented. Regulatory submissions for remibrutinib as a treatment for CSU on track for filing in 1H 2025. “Conditions like CSU and HS are more than just skin deep, often having a profound impact on patients' daily lives and activities,\" said Angelika Jahreis, Global Head, Development, Immunology, Novartis. \"These data at AAAAI and AAD highlight our continued commitment to reimagine medicine and address treatment gaps for people with immune-mediated diseases. We are particularly excited about the potential for remibrutinib as a novel oral treatment for patients with CSU who remain symptomatic on antihistamines.”","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-data-presentations-aaaai-aad-140000676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4578","BK4532","IE0002141913.USD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0211331839.USD","IE0009355771.USD","BK4585","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","BK4007","BK4588","NVS"],"gpt_icon":0},{"id":"2514326988","title":"Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514326988","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514326988?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:39","pubTimestamp":1740746340,"startTime":"0","endTime":"0","summary":"If approved,Fabhalta will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5. Phase III data demonstrated clinically meaningful 35.1% proteinuria reduction6; also, a stabilization of estimated glomerular filtration rate  – a key measure of kidney function – was observed6-8. C3G is typically diagnosed in young adults2-5; approximately half of patients progress to kidney failure within 10 years of diagnosis2-5. Regulatory reviews for C3G are ongoing in US, China and Japan; Novartis continues to advance multiple potential treatments for kidney diseases with high unmet need","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/novartis-oral-fabhalta-iptacopan-receives-123900422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","IE0009355771.USD","IE00B4R5TH58.HKD","BK4201","IE00B2B36J28.USD","BK4007","LU0211331839.USD","BK4578","IE0002141913.USD","NVS","BK4087","IE00BJJMRZ35.SGD","BK4532","BK4588","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","CHMP","EC"],"gpt_icon":0},{"id":"2514896713","title":"Salesforce Stock Falls On Weak Revenue Outlook Amid Artificial Intelligence Push","url":"https://stock-news.laohu8.com/highlight/detail?id=2514896713","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514896713?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:18","pubTimestamp":1740604716,"startTime":"0","endTime":"0","summary":"Salesforce stock fell after the company's revenue guidance for fiscal 2026 came in below expectations, despite the ramp of new AI products.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2023/01/TECH1_salesforce_012723_shutter-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2023/01/TECH1_salesforce_012723_shutter-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/salesforce-stock-salesforce-earnings-q42024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4579","LU0109394709.USD","IE00B19Z8X17.USD","LU0889565833.HKD","LU1814569148.SGD","LU0234572021.USD","LU1066051498.USD","IE00BQXX3D17.EUR","LU0642271901.SGD","LU0130102774.USD","LU0689472784.USD","LU2361044865.SGD","LU0528227936.USD","LU0943347566.SGD","LU0719512351.SGD","LU0198837287.USD","LU0289739699.SGD","LU2756315318.SGD","BK4535","BK4583","LU1585245621.USD","LU0251131958.USD","BK7142","LU1791710582.SGD","LU0109392836.USD","LU0251142724.SGD","LU1923623000.USD","IE00B19Z8W00.USD","LU1823568750.SGD","BK4528","LU2265009873.SGD","CRM.AU","LU2756315664.SGD","LU0320765992.SGD","CRM","LU0267386448.USD","LU2361044949.HKD","GILD","IE00B19Z9505.USD","BK4505","LU0069063385.USD","LU1989764664.SGD","BK4578","LU1989764748.USD","LU1430594728.SGD","LU1804176565.USD","LU0106261372.USD","LU0689626769.HKD","LU2461242641.AUD","LU0820562030.AUD"],"gpt_icon":1},{"id":"2514869258","title":"Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2514869258","media":"Benzinga","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514869258?lang=en_us&edition=fundamental","pubTime":"2025-02-27 02:30","pubTimestamp":1740594636,"startTime":"0","endTime":"0","summary":"A federal court rejected Novartis Pharmaceuticals’, a unit of Novartis AG  legal challenge to the Medicare Drug Price Negotiation Program, ruling that the program does not violate constitutional protections against excessive fines, unlawful takings, or compelled speech.The court determined that pharmaceutical manufacturers are not legally required to participate in the program, and those that do must adhere to its terms.Also Read: Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal. For over 30 years, Congress has imposed price ceilings on prescription drugs purchased by federal agencies, including the Departments of Defense and Veterans Affairs.These agencies also have the authority to negotiate prices below these limits. The Inflation Reduction Act of 2022 expanded this model by granting the Department of Health and Human Services  similar authority to negotiate prices for Medicare-covered drugs that lack generic competition and const","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/court-dismisses-novartis-challenge-medicare-183036516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BJT1NW94.SGD","BK4208","IE0002141913.USD","HHS","BK4009","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4588","LU2637428348.USD","LU0211331839.USD","IE0009355771.USD","IE00B2B36J28.USD","LU1894683264.USD","LU2346227817.USD","BK4585","NVS","BK4532","LU1894683348.USD","CMS","IE00B4R5TH58.HKD","BK4007","BK4578"],"gpt_icon":0},{"id":"2514854180","title":"Novartis Stockholder Sandoz to Reportedly Sell 26.5 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854180","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514854180?lang=en_us&edition=fundamental","pubTime":"2025-02-26 23:28","pubTimestamp":1740583733,"startTime":"0","endTime":"0","summary":"Novartis  stockholder Sandoz Family Foundation is selling about 26.5 million Novartis shares in a transaction expected to raise 2.6 billion Swiss francs , multiple media outlets reported Wednesday, citing Goldman Sachs .Emasan AG, the investment arm of the Sandoz Family Foundation, priced the shares at 98.25 Swiss francs each, according to the reports.The transaction, managed by Goldman Sachs through an accelerated bookbuilt offering, corresponds to roughly 1% of Novartis' outstanding shares, Reuters reported.A Sandoz spokesperson told the Swiss financial news agency AWP that the sale is part of a diversification strategy but did not disclose further details, Swissinfo reported.\"The vast majority of our shareholders are institutional investors with a long-term view, and we expect this to continue,\" Novartis reportedly told Reuters.Novartis, the Sandoz Family Foundation, and Goldman Sachs did not immediately respond to requests for comment from MT Newswires. Emasan could not be reached ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJJMRZ35.SGD","BK4552","LU1868836914.USD","BK4127","LU2471134952.CNY","LU2237443978.SGD","IE00BFTCPJ56.SGD","LU1868837300.USD","LU2237443622.USD","LU2471134796.USD","IE00B4R5TH58.HKD","LU0061475181.USD","IE0002141913.USD","BK4578","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU1668664300.SGD","LU2237443895.HKD","BK4550","IE00B19Z3581.USD","BK4585","IE00BFXG1179.USD","LU2471134523.USD","LU2750360641.GBP","BK4504","LU0096364046.USD","LU2237443549.SGD","LU2750360997.AUD","IE0004086264.USD","BK4532","IE00B19Z3B42.SGD","LU0211331839.USD","IE0004091025.USD","LU2237443382.USD","NVS","IE0009355771.USD","LU1868837136.USD","LU1868836757.USD","LU2471134879.HKD","LU2237443465.HKD","LU1791807156.HKD","LU1868836591.USD","LU2237438978.USD","IE0034235188.USD","BK4588","BK4007","IE00BSNM7G36.USD","BK4533","IE0002270589.USD","LU0106831901.USD"],"gpt_icon":0},{"id":"2514852178","title":"Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2514852178","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514852178?lang=en_us&edition=fundamental","pubTime":"2025-02-26 22:19","pubTimestamp":1740579540,"startTime":"0","endTime":"0","summary":"It was a busy week for the biotech sector. While the fourth-quarter earnings season is nearing the end, other pipeline and regulatory updates were in focus.bluebird bio’s BLUE shares plunged after the company announced that it has entered into a definitive agreement to be acquired by funds managed by global investment firms Carlyle and SK Capital Partners, LP.Gilead Sciences, Inc. GILD announced that the European Medicines Agency  has validated the company’s marketing authorization application and EU-Medicines for all applications for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir. Gilead is seeking approval for lenacapavir for the prevention of HIV as pre-exposure prophylaxis .Both these applications are being assessed under an accelerated assessment review timeline as the EMA’s Committee for Medicinal Products for Human Use  determined that twice-yearly lenacapavir for HIV prevention is a product of major interest for public health and therapeutic innovation.BioMarin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-blue-down-141900146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B19Z3581.USD","LU0234570918.USD","LU1585245621.USD","GILD","LU1839511570.USD","IE00B3T34201.USD","LU2087621335.USD","LU0289739699.SGD","CHMP","LU1430594728.SGD","LU2089984988.USD","IE00BZ1G4Q59.USD","LU0058720904.USD","IE0002270589.USD","BK4139","BLUE","BK4588","LU2468319806.SGD","BK4583","IE00B7SZLL34.SGD","LU0320765992.SGD","LU1066051498.USD","IE00BSNM7G36.USD","BK4087","LU1066053197.SGD","BK4585","BK4550","BK4532","BMRN","IE00B19Z3B42.SGD","BK4556","LU1571399168.USD","BK4568","TRDA","IE00BKVL7J92.USD","LU0889565916.HKD","BK4566","BK4578","LU0109394709.USD"],"gpt_icon":0},{"id":"2514872836","title":"The Zacks Analyst Blog Highlights Charles Schwab, Gilead, Medtronic, Cooper-Standard and Rave Restaurant","url":"https://stock-news.laohu8.com/highlight/detail?id=2514872836","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514872836?lang=en_us&edition=fundamental","pubTime":"2025-02-26 18:39","pubTimestamp":1740566340,"startTime":"0","endTime":"0","summary":"Chicago, IL – February 26, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: The Charles Schwab Corp. SCHW, Gilead Sciences, Inc. GILD, Medtronic plc MDT, Cooper-Standard Holdings Inc. CPS and Rave Restaurant Group, Inc. RAVE.Top Stock Reports for Chas Schwab, Gilead and Medtronic. The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Try Again to Ramp Higher","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-analyst-blog-highlights-charles-103900577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2271345857.HKD","LU0011850046.USD","LU2264538146.SGD","LU0320765489.SGD","LU0976567544.SGD","BK4139","LU0345774631.USD","SG9999014039.USD","BK4127","LU0265550359.USD","RAVE","LU0106831901.USD","LU0130102774.USD","IE00BSNM7G36.USD","BK4578","BK4568","LU1066053197.SGD","LU2089984988.USD","LU0648001328.SGD","LU0496365809.HKD","IE0002270589.USD","LU2468319806.SGD","LU1064131342.USD","IE00B7SZLL34.SGD","BK4124","LU1116320737.USD","NIM","IE00BQXX3F31.USD","IE00BZ1G4Q59.USD","LU0211331839.USD","SCHW","LU1116320901.HKD","CPS","LU1668664300.SGD","LU2089284900.SGD","LU0208291251.USD","LU1430594728.SGD","MDT","LU1989764748.USD","LU1069347547.HKD","BK4589","LU0072461881.USD","LU0266013472.USD","BK4532","BK4581","IE00BQXX3C00.GBP","LU1983299246.USD","GILD","LU2360107671.USD","BK4533"],"gpt_icon":0},{"id":"2514384268","title":"Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors","url":"https://stock-news.laohu8.com/highlight/detail?id=2514384268","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514384268?lang=en_us&edition=fundamental","pubTime":"2025-02-26 17:05","pubTimestamp":1740560700,"startTime":"0","endTime":"0","summary":"Chicago, IL – February 26, 2025 – Stocks in this week’s article are Gilead Sciences GILD, Exelixis EXEL, Synchrony Financial SYF and Molson Coors TAP.4 PEG-Based GARP Stocks to Weather 2025 Market Uncertainty. The new year has been turbulent so far for the equity market, with geopolitical tensions and trade policies playing a significant role in shaping investor sentiment. Trump's tariff policies have not only reignited trade conflicts with China but also resulted in retaliatory measures from the European Union. This has increased concerns over global supply chains and corporate earnings.Several stocks, which have surged significantly in the recent past, show an overwhelming success of this hybrid investing strategy over pure-play value and growth investments. Here, we will discuss the success of four such stocks. These are Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors.Unfortunately, this ratio is often neglected due to investors' limitations in calculating the future","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zacks-com-featured-highlights-gilead-090500682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BZ1G4Q59.USD","LU0306807586.USD","GILD","BK4139","BK4561","IE00BMG7P926.USD","IE00BMG7P587.USD","IE00BD4GTV84.USD","LU0109394709.USD","LU0321505868.SGD","IE00B19Z3581.USD","LU0058720904.USD","LU1585245621.USD","LU0234570918.USD","LU0306806265.USD","LU0106831901.USD","LU1861217088.USD","LU2360107671.USD","BK4568","PEG","IE00BSNM7G36.USD","IE0002270589.USD","BK4550","IE00B19Z3B42.SGD","BK4585","LU0321505439.SGD","LU0985481810.HKD","LU1571399168.USD","LU1861220207.SGD","BK4208","LU2087621335.USD","LU1066051498.USD","BK4158","BK4578","EXEL","LU1430594728.SGD","LU1668664300.SGD","LU0225771236.USD","LU1839511570.USD","IE00B7SZLL34.SGD","SYF","IE00BKVL7J92.USD","LU0289739699.SGD","BK4588","LU0889565916.HKD","IE00BD4GTW91.USD","LU1066053197.SGD","LU1791807156.HKD","LU2468319806.SGD","TAP"],"gpt_icon":0},{"id":"2514554012","title":"Market Chatter: Emasan Offering to Sell 1.2% Stake in Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514554012","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514554012?lang=en_us&edition=fundamental","pubTime":"2025-02-26 01:19","pubTimestamp":1740503956,"startTime":"0","endTime":"0","summary":"Novartis  stakeholder Emasan is offering to sell around 26.5 million shares, or a 1.2% stake, in the pharmaceutical company, Bloomberg reported Tuesday.The deal could raise around 2.7 billion Swiss francs , based on Tuesday's closing share price, according to the report.Emasan is selling the stake through an accelerated placement with investors, the report said.Novartis did not immediately reply to a request for comment from MT Newswires.NVS shares were 0.8% higher in recent trading.Price: 110.09, Change: +0.87, Percent Change: +0.80","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","IE00BJJMRZ35.SGD","BK4588","BK4578","IE0009355771.USD","BK4585","IE0002141913.USD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4532","IE00BFTCPJ56.SGD","LU0211331839.USD","NVS","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2514012612","title":"Novartis holder Emasan selling 26.5M shares, Bloomberg reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2514012612","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514012612?lang=en_us&edition=fundamental","pubTime":"2025-02-26 01:13","pubTimestamp":1740503625,"startTime":"0","endTime":"0","summary":"Emasan AG is offering around 26.5M shares in Swiss Novartis (NVS) through Goldman Sachs, potentially raising $3B, Pablo Mayo Cerqueiro of Bloomberg...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novartis-holder-emasan-selling-26-5m-shares-bloomberg-reports?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novartis-holder-emasan-selling-26-5m-shares-bloomberg-reports?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4585","IE00B4R5TH58.HKD","LU1868836757.USD","BK4533","IE0002141913.USD","LU2750360641.GBP","LU2471134796.USD","IE00BJJMRZ35.SGD","BK4532","BK4550","BK4516","LU0106831901.USD","IE0004086264.USD","IE0009355771.USD","IE00BSNM7G36.USD","BK4007","BK4504","LU2750360997.AUD","LU1868837136.USD","IE00BFTCPJ56.SGD","IE00BFXG1179.USD","LU1868836591.USD","LU2471134952.CNY","IE00BJT1NW94.SGD","LU1668664300.SGD","IE0002270589.USD","LU1868837300.USD","LU0061475181.USD","LU0211331839.USD","LU2237443978.SGD","LU1868836914.USD","BK4552","BK4578","LU2237443549.SGD","NVS","IE00B19Z3B42.SGD","LU2237443622.USD","LU2471134523.USD","LU2237443382.USD","IE0034235188.USD","LU0096364046.USD","IE00B2B36J28.USD","LU2471134879.HKD","LU2237443895.HKD","BK4588","IE0004091025.USD","LU2237438978.USD","LU1791807156.HKD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2514014279","title":"Emasan files to sell 26.5M shares of Novartis, Bloomberg reports","url":"https://stock-news.laohu8.com/highlight/detail?id=2514014279","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514014279?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:50","pubTimestamp":1740502215,"startTime":"0","endTime":"0","summary":"11:49 EST Emasan files to sell 26.5M shares of Novartis (NVS), Bloomberg reports Published first on TheFly – the ultimate source for real-time, mar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/emasan-files-to-sell-26-5m-shares-of-novartis-bloomberg-reports?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/emasan-files-to-sell-26-5m-shares-of-novartis-bloomberg-reports?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009355771.USD","BK4007","IE00B4R5TH58.HKD","NVS","LU0211331839.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4588","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","BK4532","IE00B2B36J28.USD","BK4585","BK4578"],"gpt_icon":0},{"id":"2514012738","title":"4 PEG-Based GARP Picks to Weather 2025 Market Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2514012738","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514012738?lang=en_us&edition=fundamental","pubTime":"2025-02-26 00:07","pubTimestamp":1740499620,"startTime":"0","endTime":"0","summary":"The new year has been turbulent so far for the equity market, with geopolitical tensions and trade policies playing a significant role in shaping investor sentiment. Trump's tariff policies have not only reignited trade conflicts with China but also resulted in retaliatory measures from the European Union. This has increased concerns over global supply chains and corporate earnings. Further, the Federal Reserve’s decision to hold interest rates steady, despite earlier expectations of a cut, has added to market uncertainty. Fed’s cautious approach suggests that inflationary pressure might still be at play, limiting its flexibility in easing monetary policy.In such a situation, investments always need to be prudently hedged in order to limit losses related to external shocks. A question that often arises is whether one should resort to a value strategy that seeks discounted stocks or opt for growth investing in times of extreme market instability. The investing track of the Oracle of Oma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/4-peg-based-garp-picks-160700050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","IE00BMG7P587.USD","TAP","IE00BMG7P819.SGD","LU0321505439.SGD","LU1861220207.SGD","LU0306807586.USD","LU0225284248.USD","GARP","LU1839511570.USD","LU2089984988.USD","BK4532","LU2087621335.USD","LU0225771236.USD","LU1066053197.SGD","IE00BD4GTV84.USD","LU0106831901.USD","PEG","EXEL","LU0889565916.HKD","LU1668664300.SGD","BK4566","BK4588","LU1791807156.HKD","IE00BMG7P926.USD","GILD","IE00BKVL7J92.USD","BK4585","LU0985481810.HKD","LU1585245621.USD","SYF","LU0234570918.USD","LU1571399168.USD","LU1066051498.USD","BK4568","BK4208","LU0289739699.SGD","BK4578","BK4166","LU0306806265.USD","IE00BMG7P694.USD","IE0002270589.USD","IE00B7SZLL34.SGD","LU2468319806.SGD","LU1861217088.USD","IE00BD4GTW91.USD","IE00B3T34201.USD","BK4550","IE00B19Z3B42.SGD","LU1430594728.SGD"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":60}]}}